| Literature DB >> 30623772 |
Henri-Corto Stoeklé1, Ninon Forster2, Mauro Turrini3, Philippe Charlier4, Christian Hervé5, Jean-François Deleuze6, Guillaume Vogt7.
Abstract
In France, genetic data are not covered by property laws. They are considered to be equivalent to a part of the human body, to be protected rather than as something of economic value. However, in this highly competitive world, France must find solutions to increase the scientific and economic values of its genetic data. One possibility would be to define genetic data as raw information with no value for use. The choice of such a value of use (clinical, scientific, economic, etc.), following various key analysis and treatment processes will thus transform genetic data into useful information. In this case, and under certain conditions, intellectual property law could consider this information to be an original creation with an economic value, whilst maintaining current levels of protection for genetic data. France thus faces a choice between changing its laws concerning the protection of genetic data, bringing them into line with the North American approach, according to which data are a form of capital that everyone has the right to increase or sell, and making the distinction between genetic data and information clearer.Entities:
Mesh:
Year: 2019 PMID: 30623772 DOI: 10.1051/medsci/2018291
Source DB: PubMed Journal: Med Sci (Paris) ISSN: 0767-0974 Impact factor: 0.818